Crossmark Global Holdings Inc. Acquires New Position in Becton, Dickinson and Company (NYSE:BDX)

Crossmark Global Holdings Inc. bought a new position in shares of Becton, Dickinson and Company (NYSE:BDX) during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor bought 24,087 shares of the medical instruments supplier’s stock, valued at approximately $4,720,000.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the stock. Vanguard Group Inc. raised its position in Becton, Dickinson and by 8.5% in the 2nd quarter. Vanguard Group Inc. now owns 17,255,948 shares of the medical instruments supplier’s stock valued at $3,366,809,000 after purchasing an additional 1,353,780 shares in the last quarter. BlackRock Inc. raised its position in shares of Becton, Dickinson and by 2,427.8% during the 1st quarter. BlackRock Inc. now owns 16,542,028 shares of the medical instruments supplier’s stock worth $3,034,470,000 after acquiring an additional 15,887,611 shares in the last quarter. State Street Corp raised its position in shares of Becton, Dickinson and by 3.5% during the 2nd quarter. State Street Corp now owns 10,270,221 shares of the medical instruments supplier’s stock worth $2,003,834,000 after acquiring an additional 342,873 shares in the last quarter. JPMorgan Chase & Co. raised its position in shares of Becton, Dickinson and by 6.5% during the 1st quarter. JPMorgan Chase & Co. now owns 3,967,843 shares of the medical instruments supplier’s stock worth $727,863,000 after acquiring an additional 242,081 shares in the last quarter. Finally, Northern Trust Corp raised its position in shares of Becton, Dickinson and by 4.0% during the 2nd quarter. Northern Trust Corp now owns 2,813,937 shares of the medical instruments supplier’s stock worth $549,028,000 after acquiring an additional 106,966 shares in the last quarter. 86.01% of the stock is currently owned by hedge funds and other institutional investors.

Becton, Dickinson and Company (NYSE:BDX) opened at $220.46 on Wednesday. Becton, Dickinson and Company has a 1-year low of $161.29 and a 1-year high of $225.23. The firm has a market capitalization of $50,064.30, a price-to-earnings ratio of 23.18, a PEG ratio of 1.72 and a beta of 1.04. The company has a debt-to-equity ratio of 1.48, a current ratio of 5.56 and a quick ratio of 5.01.

Becton, Dickinson and (NYSE:BDX) last released its quarterly earnings results on Thursday, November 2nd. The medical instruments supplier reported $2.40 earnings per share for the quarter, topping the Zacks’ consensus estimate of $2.37 by $0.03. The company had revenue of $3.17 billion during the quarter, compared to analysts’ expectations of $3.14 billion. Becton, Dickinson and had a return on equity of 22.51% and a net margin of 8.52%. The business’s revenue for the quarter was down 2.0% compared to the same quarter last year. During the same period in the previous year, the firm posted $2.12 earnings per share. equities research analysts anticipate that Becton, Dickinson and Company will post 10.63 EPS for the current year.

A number of research analysts recently issued reports on BDX shares. Piper Jaffray Companies restated a “buy” rating and set a $213.00 price target on shares of Becton, Dickinson and in a research note on Tuesday, September 12th. Zacks Investment Research downgraded Becton, Dickinson and from a “hold” rating to a “sell” rating in a research note on Monday, October 9th. Royal Bank Of Canada reiterated a “hold” rating and issued a $210.00 target price on shares of Becton, Dickinson and in a research note on Wednesday, October 25th. Wells Fargo & Company began coverage on Becton, Dickinson and in a research note on Friday, September 22nd. They issued an “outperform” rating and a $225.00 target price on the stock. Finally, Bank of America Corporation reiterated a “buy” rating and issued a $225.00 target price (up from $200.00) on shares of Becton, Dickinson and in a research note on Friday, July 21st. Five analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus price target of $213.47.

In other news, EVP Linda M. Tharby sold 4,695 shares of Becton, Dickinson and stock in a transaction on Tuesday, August 22nd. The stock was sold at an average price of $200.48, for a total value of $941,253.60. Following the completion of the sale, the executive vice president now owns 18,670 shares of the company’s stock, valued at $3,742,961.60. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Gary M. Cohen sold 15,512 shares of Becton, Dickinson and stock in a transaction on Monday, September 11th. The shares were sold at an average price of $203.77, for a total value of $3,160,880.24. Following the completion of the sale, the insider now directly owns 95,781 shares of the company’s stock, valued at approximately $19,517,294.37. The disclosure for this sale can be found here. In the last ninety days, insiders sold 47,038 shares of company stock valued at $9,480,225. Company insiders own 1.40% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Crossmark Global Holdings Inc. Acquires New Position in Becton, Dickinson and Company (NYSE:BDX)” was posted by Week Herald and is the property of of Week Herald. If you are viewing this news story on another publication, it was copied illegally and reposted in violation of US & international copyright & trademark legislation. The original version of this news story can be accessed at https://weekherald.com/2017/11/15/24087-shares-in-becton-dickinson-and-company-bdx-acquired-by-crossmark-global-holdings-inc.html.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

Institutional Ownership by Quarter for Becton, Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply